Here’s a breakdown of the key information from the NPR segment about GLP-1 drugs for weight loss,organized for clarity:
New Developments & Options:
* Wegovy Pill Approved: The FDA approved a pill version of Wegovy (containing semaglutide) on December 22nd. It’s as effective as the injection.
* Eli Lilly Pill: A competing pill from Eli Lilly is expected to be approved this year.
* Preference for pills: People generally prefer pills over injections.
Pricing (as of January 2026):
* Trump Management Deal: Drug companies initially promised a $150/month price for those not using insurance (starting dose).
* Wegovy Pill Pricing:
* Starting dose: $150/month
* higher doses: $300/month (effective Jan 5th)
* Eli Lilly Pill Pricing: $400/month
* Insurance Co-pays: Perhaps as low as $25/month with insurance coverage, but this depends on the list price and insurance plan.
* Brand-Name Discounts: Novo Nordisk and Eli Lilly are offering discounts on their brand-name drugs to patients not using insurance, to compete with compounded versions.
Impact of Compounded Versions:
* Shortages Led to Compounding: Popularity of brand-name drugs caused shortages, opening the door for compounding pharmacies.
* Lower Prices from Compounding: Compounded versions (made with the same active ingredient) are cheaper.
* Competition Drives Down Prices: Compounding pharmacies forced brand-name manufacturers to offer discounts.
Insurance Coverage:
* Becoming More Restrictive: Insurance coverage for weight loss drugs is generally becoming more limited.
* BMI requirements: Some insurers may only cover GLP-1s for those with a BMI over 40 (obesity is defined as a BMI of 30 or higher).
* Potential for Enhancement: As the FDA approves new uses for GLP-1s, insurance coverage could broaden in 2026 and beyond.